<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04801693</url>
  </required_header>
  <id_info>
    <org_study_id>1462-0001</org_study_id>
    <secondary_id>2021-000208-39</secondary_id>
    <nct_id>NCT04801693</nct_id>
  </id_info>
  <brief_title>A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated and Taken up by the Body With or Without Food</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1819479 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled Parallel Group Design) and Effect of Food on the Relative Bioavailability of BI 1819479 (Open-label, Randomised, Two-way Crossover Design)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objectives of the single rising doses (SRD) trial part are to investigate safety,&#xD;
      tolerability and pharmacokinetics (PK) of BI 1819479 in healthy male subjects following&#xD;
      administration of single rising doses.&#xD;
&#xD;
      The main objective of the food effect part is to investigate the influence of food on the&#xD;
      relative bioavailability of BI 1819479.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 26, 2021</start_date>
  <completion_date type="Anticipated">April 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 4, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>single rising dose part is single-blind, randomized, placebo-controlled within parallel dose groups.&#xD;
food effect part is randomized, open-label, two-way, two-period, crossover design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with drug-related adverse events</measure>
    <time_frame>Up to Day 36</time_frame>
    <description>Single rising doses (SRD) part</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)</measure>
    <time_frame>Up to Day 31</time_frame>
    <description>Food effect part</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>Up to Day 31</time_frame>
    <description>Food effect part</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum measured concentration of the analyte in plasma (Cmax)</measure>
    <time_frame>Up to Day 31</time_frame>
    <description>SRD part</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)</measure>
    <time_frame>Up to Day 31</time_frame>
    <description>SRD part</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve of the analyte over the time interval from 0 extrapolated to infinity (AUC0-âˆž)</measure>
    <time_frame>Up to Day 31</time_frame>
    <description>Food effect part</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 1819479</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single rising doses (SRD) part</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single rising doses (SRD) part</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1819479 fed - fasted arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Food effect part</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 1819479 fasted - fed arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Food effect part</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1819479</intervention_name>
    <description>BI 1819479</description>
    <arm_group_label>BI 1819479</arm_group_label>
    <arm_group_label>BI 1819479 fasted - fed arm</arm_group_label>
    <arm_group_label>BI 1819479 fed - fasted arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male subjects according to the assessment of the investigator, as based on a&#xD;
             complete medical history including a physical examination, vital signs (BP, PR),&#xD;
             12-lead ECG, and clinical laboratory tests&#xD;
&#xD;
          2. Age of 18 to 50 years (inclusive)&#xD;
&#xD;
          3. BMI of 18.5 to 29.9 kg/m2 (inclusive)&#xD;
&#xD;
          4. Signed and dated written informed consent prior to admission to the study, in&#xD;
             accordance with GCP and local legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any finding in the medical examination (including BP, PR or ECG) deviating from normal&#xD;
             and assessed as clinically relevant by the investigator&#xD;
&#xD;
          2. Repeated measurement of systolic blood pressure outside the range of 90 to 140 mmHg,&#xD;
             diastolic blood pressure outside the range of 50 to 90 mmHg, or pulse rate outside the&#xD;
             range of 50 to 90 bpm&#xD;
&#xD;
          3. Any laboratory value outside the reference range that the investigator considers to be&#xD;
             of clinical relevance, in particular, hepatic parameters (ALT/AST) or renal parameters&#xD;
             (creatinine) exceeding the ULN after repeated measurements&#xD;
&#xD;
          4. Any evidence of a concomitant disease assessed as clinically relevant by the&#xD;
             investigator&#xD;
&#xD;
          5. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          6. Cholecystectomy or other surgery of the gastrointestinal tract that could interfere&#xD;
             with the pharmacokinetics of the trial medication (except appendectomy or simple&#xD;
             hernia repair)&#xD;
&#xD;
          7. Diseases of the central nervous system (including but not limited to any kind of&#xD;
             seizures or stroke), and other relevant neurological or psychiatric disorders&#xD;
&#xD;
          8. History of relevant orthostatic hypotension, fainting spells, or blackouts -Further&#xD;
             exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CRS Clinical Research Services Mannheim GmbH</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Kalsch</last_name>
      <phone>+49 (621) 150450</phone>
      <email>brigitte.kalsch@crs-group.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:&#xD;
studies in products where Boehringer Ingelheim is not the license holder;&#xD;
studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;&#xD;
studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).&#xD;
For more details refer to: https://www.mystudywindow.com/msw/datasharing</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

